63118
document
Mitigation of sociocommunicational deficits of autism through oxytocin-induced recovery of medial prefrontal activity : a randomized trial . IMPORTANCE Sociocommunicational deficits make it difficult for individuals with autism spectrum disorders ( ASD ) to understand communication content with conflicting verbal and nonverbal information . Despite growing prospects for oxytocin as a therapeutic agent for ASD , no direct neurobiological evidence exists for oxytocin 's beneficial effects on this core symptom of ASD . This is slowing clinical application of the neuropeptide . OBJECTIVE To directly examine whether oxytocin has beneficial effects on the sociocommunicational deficits of ASD using both behavioral and neural measures . DESIGN , SETTING , AND PARTICIPANTS At the University of Tokyo Hospital , we conducted a randomized , double-blind , placebo-controlled , within-subject-crossover , single-site experimental trial in which intranasal oxytocin and placebo were administered . A total of 40 highly functioning men with ASD participated and were randomized in the trial . INTERVENTIONS Single-dose intranasal administration of oxytocin ( 24 IU ) and placebo . MAIN OUTCOMES AND MEASURES Using functional magnetic resonance imaging , we examined effects of oxytocin on behavioral neural responses of the participants to a social psychological task . In our previous case-control study using the same psychological task , when making decisions about social information with conflicting verbal and nonverbal contents , participants with ASD made judgments based on nonverbal contents less frequently with longer time and could not induce enough activation in the medial prefrontal cortex . Therefore , our main outcomes and measures were the frequency of the nonverbal information-based judgments ( NVJs ) , the response time for NVJs , and brain activity of the medial prefrontal cortex during NVJs . RESULTS Intranasal oxytocin enabled the participants to make NVJs more frequently ( P = .03 ) with shorter response time ( P = .02 ) . During the mitigated behavior , oxytocin increased the originally diminished brain activity in the medial prefrontal cortex ( P < .001 ) . Moreover , oxytocin enhanced functional coordination in the area ( P < .001 ) , and the magnitude of these neural effects was predictive of the behavioral effects ( P ≤ .01 ) . CONCLUSIONS AND RELEVANCE These findings provide the first neurobiological evidence for oxytocin 's beneficial effects on sociocommunicational deficits of ASD and give us the initial account for neurobiological mechanisms underlying any beneficial effects of the neuropeptide . TRIAL REGISTRATION umin.ac.jp/ctr Identifier : UMIN000002241 and UMIN000004393 .
63119
Intervention_Pharmacological
oxytocin-induced
63120
Intervention_Pharmacological
oxytocin
63121
Intervention_Pharmacological
oxytocin 's
63122
Intervention_Pharmacological
oxytocin
63123
Intervention_Control
placebo-controlled
63124
Intervention_Pharmacological
oxytocin
63125
Intervention_Control
placebo
63126
Intervention_Pharmacological
oxytocin ( 24 IU )
63127
Intervention_Control
placebo
63128
Intervention_Pharmacological
oxytocin
63129
Intervention_Pharmacological
oxytocin
63130
Outcome_Physical
effects of oxytocin
63131
Outcome_Mental
behavioral neural responses
63132
Outcome_Mental
frequency of the nonverbal information-based judgments ( NVJs
63133
Outcome_Physical
) , the
63134
Outcome_Mental
response time for NVJs
63135
Outcome_Physical
, and
63136
Outcome_Mental
brain activity of the medial prefrontal cortex during NVJs
63137
Outcome_Physical
.
63138
Outcome_Physical
NVJs
63139
Participant_Condition
autism
63140
Participant_Condition
individuals with autism spectrum disorders ( ASD
63141
Participant_Sample-size
total of 40
63142
Participant_Sex
men